Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors

详细信息    查看全文

• 作者：Ryan P. Wurz ; Liping H. Pettus ; Kate Ashton ; James Brown ; Jian Jeffrey Chen ; Brad Herberich ; Fang-Tsao Hong ; Essa Hu-Harrington ; Tom Nguyen ; David J. St. Jean ; Jr. ; Seifu Tadesse ; David Bauer ; Michele Kubryk ; Jinghui Zhan ; Keegan Cooke ; Petia Mitchell ; Kristin L. Andrews ; Faye Hsieh ; Dean Hickman ; Nataraj Kalyanaraman ; Tian Wu ; Darren L. Reid ; Edward K. Lobenhofer ; Dina A. Andrews ; Nancy Everds ; Roberto Guzman ; Andrew T. Parsons ; Simon J. Hedley ; Jason Tedrow ; Oliver R. Thiel ; Matthew Potter ; Robert Radinsky ; Pedro J. Beltran ; Andrew S. Tasker
• 刊名：ACS Medicinal Chemistry Letters
• 出版年：2015
• 出版时间：September 10, 2015
• 年：2015
• 卷：6
• 期：9
• 页码：987-992
• 全文大小：341K
• ISSN：1948-5875

文摘

In nonsmall cell lung cancer (NSCLC), the threonine⁷⁹⁰鈥搈ethionine⁷⁹⁰ (T790M) point mutation of EGFR kinase is one of the leading causes of acquired resistance to the first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Herein, we describe the optimization of a series of 7-oxopyrido[2,3-d]pyrimidinyl-derived irreversible inhibitors of EGFR kinase. This led to the discovery of compound 24 which potently inhibits gefitinib-resistant EGFR^L858R,T790M with 100-fold selectivity over wild-type EGFR. Compound 24 displays strong antiproliferative activity against the H1975 nonsmall cell lung cancer cell line, the first line mutant HCC827 cell line, and promising antitumor activity in an EGFR^L858R,T790M driven H1975 xenograft model sparing the side effects associated with the inhibition of wild-type EGFR.